As a service to the global R&D community, Science|Business has compiled this database of funding opportunities. Users are encouraged to let us know of funding calls that could be incorporated into the database. Please email all suggestions to [email protected]. The database will be updated daily. For rapid news about COVID-19, see our live blog.
PRACE, the Partnership for Advanced Computing in Europe, wants to hear how its resources can contribute to the mitigation of the impact of the COVID-19 pandemic.
Amount
Resources vary
Agency or Funder
Partnership for Advanced Computing in Europe
Eligibility (if available)
Academia, Research institutes, Commercial organisations based in Europe
Projects should be able to be quickly implemented and focus on increasing supplies of products to deal with the pandemic, vaccines, improving COVID-19 treatment and diagnosis, and new public health measures.
Canadian prime minister Justin Trudeau has pledged an extra C$1.1 billion to bolster vaccine research, clinical trials and national testing to fight COVID-19.
Proposals must be appropriate to the emergency situation and, therefore, allow immediate implementation and start-up in the National Health System, with concrete, early results applicable to the current situation.
Support for regional projects that use genomics to address specific, short-term needs of industry, not-for-profit bodies and the public sector in relation to COVID-19 through research in collaboration with these organisations.
Amount
Up to 250,000 CAD per region, total 1.5M CAD
Agency or Funder
Genome British Columbia
Eligibility (if available)
Regional organisations and researchers from Genome Centres
The objective of this Call for Proposals is to rapidly develop and manufacture a proven vaccine approach that can be used against the 2019-nCoV.
Agency or Funder
Norwegian Coalition for Epidemic Preparedness Innovations
Eligibility (if available)
Non-profit research organisations, for-profit companies, international organisations and foundations, joint R&D ventures, government research organisations, and academic institutions. Hold a vaccine technology that has already been proven. Propose only one 2019-nCoV vaccine candidate per application. Have the capacity to start vaccine manufacturing in at short notice. Be an organization that must be willing to transfer their vaccine technology to a global network
of large-scale manufacturers and ideally has its own large-scale manufacturing capabilities
Research is to focus on vaccines and therapeutics; and on diagnostics, clinical investigations, anthropology investigations, and development of technologies, platforms or systems to accelerate the R&D of diagnostics.
Amount
£20M
Agency or Funder
National Institute for Health Research
Eligibility (if available)
Hosted by a UK institution eligible for UKRI funding. Overseas research organisations in affected countries providing important local engagement can be co-investigators
A special call specifically designed for COVID-19 and related respiratory viral infections to ramp up national R&D efforts for new antivirals, vaccines, and affordable diagnostics.
Amount
Not specified
Agency or Funder
Science & Engineering Research Board, India
Eligibility (if available)
One of the participating institutions should have access to Biosafety Level 3 and above facilities, along with expertise of handling respiratory viruses as per WHO/Govt. of India protocols.
A call for novel therapies, broad-spectrum antivirals, next-generation vaccines that may target new corona strains, multiple corona viruses or more than one type of virus, and strategies for first responders and emergency medical personnel.
Amount
$150.000 (U.S.) guaranteed, with the potential to receive up to $1 million
Agency or Funder
Harrington Discovery Institute
Eligibility (if available)
Project lead must have an MD, PhD or equivalent and based in the U.S., UK or Canada.
The aim of the call is to gather information and stimulate funding of the development of non-animal, human biology-based models to help coordinate and accelerate responses to current and emerging pandemics
Amount
up to $40,000 (U.S. dollars)
Agency or Funder
Johns Hopkins Center for Alternatives to Animal Testing (CAAT)
Eligibility (if available)
Academic group, non-profit, or small or medium enterprise
Funding to support reasearchers from FNRS and universities of the Wallonia-Brussels Federation. Priorities lie on epidemiological and translational studies, immunology and prevention of the virus.
Amount
€60,000
Agency or Funder
Fonds de la Recherche Scientifique (FNRS)
Eligibility (if available)
Researchers from FNRS or the six universities part of the Wallonia-Brussels Federation (ULB, UCLouvain, ULiege, UMons, UNamur, USL)